Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10690778 | 0.95 | APEX1 (0.42) | APEX1ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL10685590 | 0.94 | APEX1 (0.41) | APEX1ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL10694025 | 0.92 | APEX1 (0.53) | APEX1ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL10690648 | 0.89 | TSHR (0.41) | APEX1ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL9749776 | 0.88 | APEX1 (0.44) | APEX1ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL10685537 | 0.88 | TSHR (0.39) | APEX1ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| Tiprotimod SCHEMBL9509661 | 0.87 | SMN1; SMN2 (0.35) | APEX1ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL10688579 | 0.86 | LDHA (0.40) | APEX1ALDH1A1SMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL9749252 | 0.83 | GAA (0.51) | ALDH1A1TSHRHSD17B10POLBHPGD | |
| SCHEMBL10691191 | 0.83 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2HSD17B10POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0342565-B1 | USE OF THE THIAZOLE DERIVATIVE TIPROTIMOD IN THE PREPARATION OF A MEDICAMENT FOR TREATING VIRAL INFECTIONS | BEHRINGWERKE Aktiengesellschaft (DE) | 1993-08-11 | — | — | EP | claimed |
| US-4963577-A | ADMINISTERING TO TREAT HERPES OR ENCEPHALOMYOCARDITIS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1990-10-16 | — | — | US | claimed |
| EP-0342565-A2 | Use of the thiazole derivative tiprotimod in the preparation of a medicament for treating viral infections | BEHRINGWERKE Aktiengesellschaft (DE) | 1989-11-23 | — | — | EP | claimed |
| JP-2017123-A | — | — | None | — | — | JP | disclosed |
| US-20240299363-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2024-09-12 | — | — | US | disclosed |
| US-20230310381-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2023-10-05 | — | — | US | disclosed |
| EP-3043648-B1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2023-09-20 | — | — | EP | disclosed |
| US-11701344-B2 | Bendamustine pharmaceutical compositions | VOUDOURIS VASILIOS (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220079923-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2022-03-17 | — | — | US | disclosed |
| US-20210008036-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2021-01-14 | — | — | US | disclosed |
| US-10786486-B2 | Bendamustine pharmaceutical compositions | VOUDOURIS VASILIOS (US) | 2020-09-29 | — | — | US | disclosed |
| US-4963577-A | ADMINISTERING TO TREAT HERPES OR ENCEPHALOMYOCARDITIS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1990-10-16 | — | — | US | disclosed |
| US-4963577-A | ADMINISTERING TO TREAT HERPES OR ENCEPHALOMYOCARDITIS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1990-10-16 | — | — | US | disclosed |
| US-4963577-A | ADMINISTERING TO TREAT HERPES OR ENCEPHALOMYOCARDITIS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1990-10-16 | — | — | US | disclosed |
| JP-H0217123-A | THIAZOLE DERIVATIVE FOR PRODUCING THERAPEUTIC AGENT FOR VIRAL INFECTIOUS DISEASE | BEHRINGWERKE AG | 1990-01-22 | — | — | JP | disclosed |
| EP-0342565-A2 | Use of the thiazole derivative tiprotimod in the preparation of a medicament for treating viral infections | BEHRINGWERKE Aktiengesellschaft (DE) | 1989-11-23 | — | — | EP | disclosed |
| EP-0342565-A2 | Use of the thiazole derivative tiprotimod in the preparation of a medicament for treating viral infections | BEHRINGWERKE Aktiengesellschaft (DE) | 1989-11-23 | — | — | EP | disclosed |
| EP-0342565-A2 | Use of the thiazole derivative tiprotimod in the preparation of a medicament for treating viral infections | BEHRINGWERKE Aktiengesellschaft (DE) | 1989-11-23 | — | — | EP | disclosed |
| US-4762848-A | IMMUNE SYSTEM STIMULANTS, CYTOSTATIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786486-B2 | Bendamustine pharmaceutical compositions | FLT3, BLK, FOLR2 | APEX1 4687/4885ALDH1A1 1158/4885SMN1; SMN2 509/4885 |
| US-20220079923-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | FLT3, BLK, FOLR2 | APEX1 4687/4885ALDH1A1 1158/4885SMN1; SMN2 509/4885 |
| US-20230310381-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | FLT3, BLK, FOLR2 | APEX1 4687/4885ALDH1A1 1158/4885SMN1; SMN2 509/4885 |
| US-20210008036-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | FLT3, BLK, FOLR2 | APEX1 4687/4885ALDH1A1 1158/4885SMN1; SMN2 509/4885 |
| US-11701344-B2 | Bendamustine pharmaceutical compositions | FLT3, BLK, FOLR2 | APEX1 4687/4885ALDH1A1 1158/4885SMN1; SMN2 509/4885 |
| US-20240299363-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | FLT3, BLK, FOLR2 | APEX1 4687/4885ALDH1A1 1158/4885SMN1; SMN2 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.